当前位置: 首页 >> 检索结果
241. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
作者: Iain B McInnes.;Philip J Mease.;Christopher T Ritchlin.;Proton Rahman.;Alice B Gottlieb.;Bruce Kirkham.;Radhika Kajekar.;Eumorphia-Maria Delicha.;Luminita Pricop.;Shephard Mpofu.
来源: Rheumatology (Oxford). 2017年56卷11期1993-2003页
To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA.
242. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
作者: Josef S Smolen.;Jung-Yoon Choe.;Nenad Prodanovic.;Jaroslaw Niebrzydowski.;Ivan Staykov.;Eva Dokoupilova.;Asta Baranauskaite.;Roman Yatsyshyn.;Mevludin Mekic.;Wieskawa Porawska.;Hana Ciferska.;Krystyna Jedrychowicz-Rosiak.;Agnieszka Zielinska.;Jasmine Choi.;Young Hee Rho.
来源: Rheumatology (Oxford). 2017年56卷10期1771-1779页
SB2 is a biosimilar to the reference infliximab (INF). Similar efficacy, safety and immunogenicity between SB2 and INF up to 30 weeks were previously reported. This report investigates such clinical similarity up to 54 weeks, including structural joint damage.
243. Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.
作者: Sytske Anne Bergstra.;Robert B M Landewé.;Tom W J Huizinga.;Cornelia F Allaart.
来源: Rheumatology (Oxford). 2017年56卷10期1721-1728页
To compare 10-year disease outcomes of RA patients who have continuous low disease activity and are on MTX with or without initial combination therapy with infliximab or prednisone and SSZ.
244. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.
作者: Nicole P C Konijn.;Lilian H D van Tuyl.;Maarten Boers.;Debby den Uyl.;Marieke M Ter Wee.;Lindsey K M van der Wijden.;Irene E M Bultink.;Pit J S M Kerstens.;Alexandre E Voskuyl.;Dirkjan van Schaardenburg.;Michael T Nurmohamed.;Willem F Lems.
来源: Rheumatology (Oxford). 2017年56卷9期1586-1596页
To assess the efficacy and safety of initial COBRA-light vs COBRA therapy in RA patients after a 4-year follow-up period.
245. Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.
作者: Femke B Lamers-Karnebeek.;Jolanda J Luime.;David F Ten Cate.;Steven Teerenstra.;Nanno W A A Swen.;Andreas H Gerards.;Jos Hendrikx.;Emma M van Rooyen.;Ramon Voorneman.;Cees Haagsma.;Natalja Basoski.;Mike de Jager.;Marjan Ghiti Moghadam.;Monique N Efde.;Yvonne P M Goekoop-Ruiterman.;Piet L C M van Riel.;Johannes W G Jacobs.;Tim L Jansen.
来源: Rheumatology (Oxford). 2017年56卷9期1560-1565页
Ultrasonography (US) can be used for treatment decisions in RA patients. This study investigated the added value of US to clinical variables in predicting flare in RA patients with longstanding low disease activity when stopping TNF inhibitors (TNFi).
246. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
作者: Désirée van der Heijde.;Maxime Dougados.;Robert Landewé.;Joachim Sieper.;Walter P Maksymowych.;Martin Rudwaleit.;Filip Van den Bosch.;Jürgen Braun.;Philip J Mease.;Alan J Kivitz.;Jessica Walsh.;Owen Davies.;Lars Bauer.;Bengt Hoepken.;Luke Peterson.;Atul Deodhar.
来源: Rheumatology (Oxford). 2017年56卷9期1498-1509页
The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA.
247. Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.
作者: Regina Rendas-Baum.;Mark Kosinski.;Amitabh Singh.;Charles A Mebus.;Bethany E Wilkinson.;Gene V Wallenstein.
来源: Rheumatology (Oxford). 2017年56卷8期1386-1394页
RA causes high disability levels and reduces health-related quality of life, triggering increased costs and risk of unemployment. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. These post hoc analyses of phase 3 data aimed to assess monthly medical expenditure (MME) and risk of job loss for tofacitinib treatment vs placebo.
248. Long-term effects of a lifestyle intervention and oral glucosamine sulphate in primary care on incident knee OA in overweight women.
作者: Bastiaan C de Vos.;Marieke L A Landsmeer.;Marienke van Middelkoop.;Edwin H G Oei.;Marjolein Krul.;Sita M A Bierma-Zeinstra.;Jos Runhaar.
来源: Rheumatology (Oxford). 2017年56卷8期1326-1334页
The present study was designed to evaluate the effect of a lifestyle intervention aimed to reduce body weight and of oral glucosamine sulphate on the incidence of knee osteoarthritis (OA) after 6-7 years in a population of middle-aged, overweight women, without knee OA at baseline.
249. Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time.
作者: Xenofon Baraliakos.;Joachim Sieper.;Su Chen.;Aileen L Pangan.;Jaclyn K Anderson.
来源: Rheumatology (Oxford). 2017年56卷7期1162-1166页
In patients with active axial spondyloarthritis (axSpA), inflammation in the SIJ or spine on MRI, an elevated CRP level or both are considered useful objective assessments for disease activity and initiation of TNF antagonists. The aim of this post hoc analysis of the randomized, double-blind ABILITY-1 study (NCT00939003) was to assess changes in objective inflammation over time.
250. Bone curvature changes can predict the impact of treatment on cartilage volume loss in knee osteoarthritis: data from a 2-year clinical trial.
作者: Jean-Pierre Raynauld.;Jean-Pierre Pelletier.;Philippe Delorme.;Pierre Dodin.;François Abram.;Johanne Martel-Pelletier.
来源: Rheumatology (Oxford). 2017年56卷6期989-998页
Knee bone curvature assessed by MRI was associated with OA cartilage loss. A recent knee OA trial demonstrated the superiority of chondroitin sulfate over celecoxib (comparator) at reducing cartilage volume loss (CVL) in the medial compartment (condyle). The main objectives were to identify which baseline bone curvature regions of interest (BCROI) best associated with CVL and investigate whether baseline BCROI and 2-year change are correlated with the protective effect of chondroitin sulphate on CVL.
251. Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate.
作者: Anna Salmela.;Niels Rasmussen.;Jan Willem Cohen Tervaert.;David R W Jayne.;Agneta Ekstrand.; .
来源: Rheumatology (Oxford). 2017年56卷6期965-972页
The aim of this study was to evaluate whether chronic nasal carriage of Staphylococcus aureus (SA) is related to relapses in patients with newly diagnosed ANCA-associated vasculitis (AAV).
252. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
作者: Chantal A M Bouman.;Aatke van der Maas.;Noortje van Herwaarden.;Eric H Sasso.;Frank H J van den Hoogen.;Alfons A den Broeder.
来源: Rheumatology (Oxford). 2017年56卷6期973-980页
The aim was to evaluate the predictive value of the baseline multi-biomarker disease activity (MBDA) score in long-standing RA patients with low disease activity tapering TNF inhibitors (TNFi) for successful tapering or discontinuation, occurrence of flare and major flare, and radiographic progression.
253. Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden.
作者: Johan K Wallman.;Anna Jöud.;Tor Olofsson.;Lennart T H Jacobsson.;Henning Bliddal.;Lars E Kristensen.
来源: Rheumatology (Oxford). 2017年56卷5期716-724页
The aim was to assess work-loss days before and after commencement of anti-TNF treatment in patients with non-radiographic axial spondylarthritis (nr-axSpA).
254. Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides.
作者: Andreas Kronbichler.;Johannes Leierer.;Gisela Leierer.;Gert Mayer.;Alina Casian.;Peter Höglund.;Kerstin Westman.;David Jayne.; .
来源: Rheumatology (Oxford). 2017年56卷5期704-708页
To assess potential associations for the development of venous thromboembolic events in patients with ANCA-associated vasculitides (AAV).
255. Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
作者: Lien T Quach.;Bei-Hung Chang.;Mary T Brophy.;Soe Soe Thwin.;Keri Hannagan.;James R O'Dell.
来源: Rheumatology (Oxford). 2017年56卷3期378-383页
The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with regard to the infectious and gastrointestinal (GI) adverse events (AEs) reported in The Rheumatoid Arthritis Comparison of Active Therapies Trial.
256. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab.
作者: Rohit Aggarwal.;Priyadarshini Loganathan.;Diane Koontz.;Zengbiao Qi.;Ann M Reed.;Chester V Oddis.
来源: Rheumatology (Oxford). 2017年56卷2期247-254页
The aim was to assess the efficacy of rituximab for the cutaneous manifestations of adult DM and JDM.
257. Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study.
作者: Lesley-Anne Bissell.;Elizabeth M A Hensor.;Lukasz Kozera.;Sarah L Mackie.;Agata N Burska.;Jacqueline L Nam.;Helen Keen.;Edith Villeneuve.;Helena Donica.;Maya H Buch.;Philip G Conaghan.;Jacqueline Andrews.;Paul Emery.;Ann W Morgan.
来源: Rheumatology (Oxford). 2016年55卷12期2181-2190页
To determine the change in established biomarkers of cardiovascular (CV) risk, namely, total cholesterol/high-density lipoprotein cholesterol ratio (TC/HDL-C), N-terminal pro-brain natriuretic peptide (NT-proBNP) and insulin resistance (IR) in patients with early RA treated with two different treat-to-target strategies.
258. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
作者: Pascal H P de Jong.;Johanna M Hazes.;Leander R Buisman.;Pieternella J Barendregt.;Derkjen van Zeben.;Peter A van der Lubbe.;Andreas H Gerards.;Mike H de Jager.;Peter B J de Sonnaville.;Bernard A Grillet.;Jolanda J Luime.;Angelique E A M Weel.
来源: Rheumatology (Oxford). 2016年55卷12期2138-2147页
To evaluate direct and indirect costs per quality adjusted life year (QALY) for different initial treatment strategies in very early RA.
259. Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis.
作者: Bruce Kirkham.;Khaldoun Chaabo.;Christopher Hall.;Toby Garrood.;Timothy Mant.;Elizabeth Allen.;Alexandra Vincent.;Joana C Vasconcelos.;Andrew T Prevost.;Gabriel S Panayi.;Valerie M Corrigall.
来源: Rheumatology (Oxford). 2016年55卷11期1993-2000页
Binding immunoglobulin protein (BiP) is a human endoplasmic reticulum-resident stress protein. In pre-clinical studies it has anti-inflammatory properties due to the induction of regulatory cells. This randomized placebo-controlled, dose ascending double blind phase I/IIA trial of BiP in patients with active RA, who had failed accepted therapies, had the primary objective of safety. Potential efficacy was measured by DAS28-ESR and changes in biomarkers.
260. Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment.
作者: Glen S Hazlewood.;Claire Bombardier.;George Tomlinson.;Carter Thorne.;Vivian P Bykerk.;Andrew Thompson.;Diane Tin.;Deborah A Marshall.
来源: Rheumatology (Oxford). 2016年55卷11期1959-1968页
To quantify the preferences of patients with early RA (ERA) with the benefits and harms of DMARDs.
|